Fgfr3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Fibroblast growth factor receptor 3 (FGFR3) is a member of the receptor tyrosine kinase (RTK) family that plays critical roles in skeletal development, tissue homeostasis, and cellular proliferation. FGFR3 binds multiple fibroblast growth factors (FGFs) with high affinity, triggering dimerization, autophosphorylation, and activation of downstream signaling pathways including MAPK/ERK, PI3K/AKT, and PLCγ. During development, FGFR3 is prominently expressed in chondrocytes where it negatively regulates bone growth, explaining why activating FGFR3 mutations cause achondroplasia, the most common form of dwarfism. In the nervous system, FGFR3 is expressed in neural progenitor cells, astrocytes, and neurons, where it regulates neurogenesis, neuronal survival, and synaptic function. Emerging evidence suggests FGFR3 signaling may play roles in neurodegenerative diseases and brain tumors.
| FGFR3 Protein | |
|---|---|
| Protein Name | FGFR3 Protein |
| Gene | FGFR3 |
| UniProt ID | P22607 |
| PDB IDs | 1RY7, 2PVF, 4K33 |
| Molecular Weight | 88.5 kDa |
| Subcellular Location | Plasma membrane |
| Protein Family | FGFR tyrosine kinase family |
FGFR3 Protein is a FGFR tyrosine kinase family. This protein contains extracellular ligand-binding domains, a transmembrane helix, and an intracellular tyrosine kinase domain that is activated upon ligand binding and dimerization.
FGFR3 (Fibroblast Growth Factor Receptor 3) is a receptor tyrosine kinase that binds FGFs. It activates MAPK, PI3K/AKT, and PLCγ pathways. FGFR3 is critical for skeletal development and bone growth. In the brain, FGFR3 is expressed in neurons and may affect synaptic function. Unlike FGFR1/FGFR2, FGFR3 often signals to inhibit cell proliferation, particularly in cartilage and bone.
FGFR3 mutations cause achondroplasia and thanatophoric dysplasia (severe skeletal dysplasias). Gain-of-function mutations lead to constitutive activation and skeletal abnormalities. FGFR3 is also implicated in AD (neuronal function) and various cancers (bladder, cervical).
Several FGFR3 inhibitors are in development for cancer and skeletal disorders. BGJ398 and LY2874455 are pan-FGFR inhibitors. No approved drugs specifically target FGFR3 for neurodegeneration.
The study of Fgfr3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.